Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 18, Issue 5, Pages 610-615Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458511426738
Keywords
Interferon-beta; multiple sclerosis; neutralizing antibodies; persistency; titer
Categories
Funding
- Bayer Schering
- Biogen Idec
- Merck Serono
- Sanofi Aventis
- Allergan
- Berlex
- Bayer
- CSL Behring
- Novartis
- Octapharma
- Roche
- Sanofi
- Betaferon, Bayer Schering Pharma
- Avonex
- Rebif
- Copaxone
- Teva Pharmaceuticals
- Tysabri
Ask authors/readers for more resources
Background: Neutralizing antibodies (NAbs) affect the efficacy of interferon-beta (IFN beta) treatment in multiple sclerosis (MS) patients, particularly if NAbs persist. Persistency depends on NAb titers, which differ between IFN beta preparations. Objective: This study evaluated IFN beta preparation-specific NAb cut-off titers during early treatment for prediction of NAb persistency. Methods: Patients who had at least one NAb test between 12 and 30 months (baseline) as well as after more than 48 months (follow-up) on IFN beta treatment were included in this longitudinal study. Results: At baseline 1064 patients had a NAb test. Of those, 203 had a follow-up test. In the follow-up group 23.2% of patients were NAb positive during baseline. NAb frequency significantly decreased by 40.7% in the IFN beta-1a and by 60% in the IFN beta-1b group at follow-up after a mean time of 75.4 months on treatment, and median NAb titers decreased significantly in both groups. During baseline, NAb titers of >258 neutralizing units (NU) had a sensitivity of 81.3% and a specificity of 90.9% in the IFN beta-1a group, whereas titers of >460 NU had a sensitivity of 100% and a specificity of 91.7% in the IFN beta-1b group to predict persistency at follow-up. When these cut-off titers are applied, 10.2% of all treated patients developed persistent NAbs. Conclusion: IFN beta preparation-specific NAb cut-off titers for prediction of NAb persistency, which may be useful in individual treatment decision making, are provided.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available